CinCor Pharma, Inc., (CINC): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
CINC Stock Price Chart Interactive Chart >
CINC Price/Volume Stats
|Current price||$19.03||52-week high||$30.66|
|Prev. close||$16.87||52-week low||$13.00|
|Day high||$19.55||Avg. volume||178,777|
|50-day MA||$19.34||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||717.62M|
CinCor Pharma, Inc., (CINC) Company Bio
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardiovascular diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension and primary aldosteronism, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Most Popular Stories View All
CINC Latest News Stream
|Loading, please wait...|
CINC Latest Social Stream
View Full CINC Social Stream
Latest CINC News From Around the Web
Below are the latest news stories about CinCor Pharma Inc that investors may wish to consider to help them evaluate CINC as an investment opportunity.
In terms of doing mergers and acquisitions and raising money through initial public offerings, 2021 was huge. But 2022 may be vastly different.
BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the appointment of the independent member June Lee, M.D. to the company’s Board of Directors. Dr. Lee brings decades of leadership experience in the biotechnology and pharmaceutical industry and has served in numerous executive and board roles. “We are very pleased to welcome June to the CinCor Board,” said James Healy, M.D., Ph.D., Chairman of CinCor’s Board of Directors. “As the Company’s clinical prog
When you’re looking for stocks to buy there are so many things you can take into account, but starting with looking at the markets themselves is a good tactic. With such a blistering performance in the benchmark indices throughout most of the post-pandemic months, it may have been inevitable that a correction would occur. Just like the real world, investor sentiment features a gravitational pull: nothing can go up forever. Having said that, not all indices have suffered equally, presenting a con
CinCor Pharma Inc.'s stock shot out of the gate in morning trading Friday, but then pulled back sharply, to trade briefly below in negative territory. The Massachusetts-based biopharmaceutical company's stock's first trade was at $21.00 at 11:05 a.m. Eastern, or 31.3% above the $16 IPO price. The stock then rose to an intraday high of $22.67, before selling off to trade as low as $15.69, or 1.9% below its IPO price, before bouncing slightly to trade flat. At current prices, the company is valued
CinCor Pharma Inc. is set to go public on the Nasdaq Friday, after the Massachusetts-based biopharmaceutical company's upsized initial public offering priced overnight at $16 a share, in the middle of the expected range of between $15 and $17 a share. The company raised $193.6 million as it sold 12.1 million shares in the IPO, up from previous expectations of an 11.0 million share offering. The IPO pricing values the company at about $566.7 million. Morgan Stanley, Jefferies and Evercore ISI are
CINC Price Returns